Buzas G, Birinyi P
Antibiotics (Basel). 2023; 12(6).
PMID: 37370265
PMC: 10295703.
DOI: 10.3390/antibiotics12060946.
Wu B, Sun C, Sun X, Li X
Medicine (Baltimore). 2022; 101(36):e30532.
PMID: 36086697
PMC: 10980492.
DOI: 10.1097/MD.0000000000030532.
Salillas S, Galano-Frutos J, Mahia A, Maity R, Conde-Gimenez M, Anoz-Carbonell E
Int J Mol Sci. 2021; 22(18).
PMID: 34576300
PMC: 8467567.
DOI: 10.3390/ijms221810137.
Kataria R, Khatkar A
BMC Chem. 2019; 13(1):41.
PMID: 31384789
PMC: 6661759.
DOI: 10.1186/s13065-019-0556-0.
Macegoniuk K, Grela E, Biernat M, Psurski M, Gosciniak G, Dzielak A
PLoS One. 2017; 12(8):e0182437.
PMID: 28792967
PMC: 5550016.
DOI: 10.1371/journal.pone.0182437.
Isolation and diagnosis of Helicobacter pylori by a new method: microcapillary culture.
Allahverdiyev A, Bagirova M, Caliskan R, Bahar Tokman H, Aliyeva H, Unal G
World J Gastroenterol. 2015; 21(9):2622-8.
PMID: 25759529
PMC: 4351211.
DOI: 10.3748/wjg.v21.i9.2622.
Medicinal plant activity on Helicobacter pylori related diseases.
Wang Y
World J Gastroenterol. 2014; 20(30):10368-82.
PMID: 25132753
PMC: 4130844.
DOI: 10.3748/wjg.v20.i30.10368.
Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment.
Adachi K, Hashimoto T, Ishihara S, Fujishiro H, Sato S, Sato H
Curr Ther Res Clin Exp. 2014; 64(7):412-21.
PMID: 24944392
PMC: 4053033.
DOI: 10.1016/S0011-393X(03)00120-6.
Detection of Helicobacter pylori in Gastric Aspirates Using a Monoclonal Antibody-Based Test.
Kim H, Kim D, Park H, Kim W, Ahn Y, Lee Y
Gut Liver. 2013; 7(1):30-4.
PMID: 23423538
PMC: 3572317.
DOI: 10.5009/gnl.2013.7.1.30.
Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
Yang J, Yang Y, Uang Y, Lin C, Wang T
Br J Clin Pharmacol. 2009; 67(5):503-10.
PMID: 19552744
PMC: 2686066.
DOI: 10.1111/j.1365-2125.2009.03393.x.
Proton pump inhibitors and gastritis.
Suzuki M, Suzuki H, Hibi T
J Clin Biochem Nutr. 2008; 42(2):71-5.
PMID: 18385822
PMC: 2266058.
DOI: 10.3164/jcbn.2008012.
Lansoprazole Novel Effector Sites Revealed by Autoradiography: Relation to Helicobacter pylori, Colon, Esophagus and Others.
Nakamura M, Matsui H, Serizawa H, Tsuchimoto K
J Clin Biochem Nutr. 2008; 41(3):154-9.
PMID: 18299709
PMC: 2243239.
DOI: 10.3164/jcbn.2007021.
Helicobacter pylori detection and antimicrobial susceptibility testing.
Megraud F, Lehours P
Clin Microbiol Rev. 2007; 20(2):280-322.
PMID: 17428887
PMC: 1865594.
DOI: 10.1128/CMR.00033-06.
Potent gastric acid inhibition in Helicobacter pylori eradication.
Gisbert J
Drugs. 2005; 65 Suppl 1:83-96.
PMID: 16335862
DOI: 10.2165/00003495-200565001-00012.
Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis.
Yeo M, Kim D, Han S, Lee J, Kim Y, Cho Y
Gut. 2005; 55(1):26-33.
PMID: 16127019
PMC: 1856363.
DOI: 10.1136/gut.2005.067454.
A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.
Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N
Antimicrob Agents Chemother. 2000; 44(11):3069-73.
PMID: 11036024
PMC: 101604.
DOI: 10.1128/AAC.44.11.3069-3073.2000.
In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
Kawakami Y, Akahane T, Yamaguchi M, Oana K, Takahashi Y, Okimura Y
Antimicrob Agents Chemother. 2000; 44(2):458-61.
PMID: 10639386
PMC: 89707.
DOI: 10.1128/AAC.44.2.458-461.2000.
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry H, Markham A
Drugs. 1999; 58(4):725-42.
PMID: 10551440
DOI: 10.2165/00003495-199958040-00014.
Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.
Richardson P, Hawkey C, Stack W
Drugs. 1998; 56(3):307-35.
PMID: 9777309
DOI: 10.2165/00003495-199856030-00002.
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Cloud M, Enas N, Humphries T, Bassion S
Dig Dis Sci. 1998; 43(5):993-1000.
PMID: 9590413
DOI: 10.1023/a:1018822532736.